Pharmaceutical Innovation and the Inflation Reduction Act: 2025 Year in Review
We follow 19 biopharma companies that have had or are likely to have a drug selected for Medicare negotiation as a result of the Inflation Reduction Act (IRA)...
Verdant’s projects examine how federal policies, market structure, and drug-level economics shape the pharmaceutical market and supply chain. Our portfolio includes grant-funded research, advisory engagements, and expert testimony in pharmaceutical matters.
The First 10 Drugs to be Negotiated by Medicare
On August 29, the Centers for Medicare & Medicaid Services announced the first 10drugs to be negotiated by Medicare. As CMS and pharmaceutical manufacturersprepare for negotiations, they will...
Pharmaceutical Innovation and the Inflation Reduction Act: 2025 Mid-Year Review
Though there was optimism coming into 2025 that conditions were improving for the industry due to growing M&A interest and hopes for monetary easing, the uncertainty created by...
The Blockbuster Orphan Paradox: Consequences Of Special Treatment Of Rare Disease Drugs In Medicare Negotiation
The One Big Beautiful Bill Act (OBBBA) of 2025 has generated controversy across numerous areas of social policy. However, one aspect of the bill has received relatively little...
The Next 15 Drugs to be Negotiated by Medicare
On January 17, 2025, the Centers for Medicare & Medicaid Services announced the next round of drugs to be negotiated by Medicare. This round includes 15 drugs, with...
Lead with Evidence
Partner with Verdant for rigorous, objective economic analysis.